These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23413042)
1. Comprehensive profiling of peripheral immune cells and subsets in patients with intermittent allergic rhinitis compared to healthy controls and after treatment with glucocorticoids. Zhang H; Cardell LO; Bjorkander J; Benson M; Wang H Inflammation; 2013 Aug; 36(4):821-9. PubMed ID: 23413042 [TBL] [Abstract][Full Text] [Related]
2. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Linden M; Svensson C; Andersson M; Greiff L; Andersson E; Denburg JA; Persson CG Allergy; 1999 Mar; 54(3):212-9. PubMed ID: 10321556 [TBL] [Abstract][Full Text] [Related]
3. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Wilson DR; Irani AM; Walker SM; Jacobson MR; Mackay IS; Schwartz LB; Durham SR Clin Exp Allergy; 2001 Nov; 31(11):1705-13. PubMed ID: 11696046 [TBL] [Abstract][Full Text] [Related]
4. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis. Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949 [TBL] [Abstract][Full Text] [Related]
5. Cytokine production in peripheral blood cells during and outside the pollen season in birch-allergic patients and non-allergic controls. Wosinska-Becler K; Plewako H; Håkansson L; Rak S Clin Exp Allergy; 2004 Jan; 34(1):123-30. PubMed ID: 14720272 [TBL] [Abstract][Full Text] [Related]
6. Effects of pollen and nasal glucocorticoid on FOXP3+, GATA-3+ and T-bet+ cells in allergic rhinitis. Malmhäll C; Bossios A; Pullerits T; Lötvall J Allergy; 2007 Sep; 62(9):1007-13. PubMed ID: 17686103 [TBL] [Abstract][Full Text] [Related]
7. Inflammatory profiles in nasal mucosa of patients with persistent vs intermittent allergic rhinitis. Liu F; Zhang J; Liu Y; Zhang N; Holtappels G; Lin P; Liu S; Bachert C Allergy; 2010 Sep; 65(9):1149-57. PubMed ID: 20192943 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of nasal mucosal eotaxin in patients with allergic rhinitis during grass pollen season: effect of a local glucocorticoid. Pullerits T; Lindén A; Praks L; Cardell LO; Lötvall J Clin Exp Allergy; 2000 Oct; 30(10):1469-75. PubMed ID: 10998025 [TBL] [Abstract][Full Text] [Related]
9. Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis. Uller L; Emanuelsson CA; Andersson M; Erjefält JS; Greiff L; Persson CG Respir Res; 2010 May; 11(1):54. PubMed ID: 20459697 [TBL] [Abstract][Full Text] [Related]
10. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1beta, TNF-alpha, or neutrophils. Benson M; Strannegård IL; Strannegård O; Wennergren G J Allergy Clin Immunol; 2000 Aug; 106(2):307-12. PubMed ID: 10932075 [TBL] [Abstract][Full Text] [Related]
11. Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. Johansson S; Keen C; Ståhl A; Wennergren G; Benson M Allergy; 2005 May; 60(5):638-42. PubMed ID: 15813809 [TBL] [Abstract][Full Text] [Related]
13. Allergen-reactive antibodies are found in nasal fluids from patients with birch pollen-induced intermittent allergic rhinitis, but not in healthy controls. Benson M; Reinholdt J; Cardell LO Allergy; 2003 May; 58(5):386-92. PubMed ID: 12752324 [TBL] [Abstract][Full Text] [Related]
14. A pathway-based approach to find novel markers of local glucocorticoid treatment in intermittent allergic rhinitis. Wang H; Chavali S; Mobini R; Muraro A; Barbon F; Boldrin D; Aberg N; Benson M Allergy; 2011 Jan; 66(1):132-40. PubMed ID: 20659080 [TBL] [Abstract][Full Text] [Related]
15. Quantitation of inflammatory cells in the nasal mucosa of patients with allergic rhinitis and normal subjects. Igarashi Y; Goldrich MS; Kaliner MA; Irani AM; Schwartz LB; White MV J Allergy Clin Immunol; 1995 Mar; 95(3):716-25. PubMed ID: 7897155 [TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In Vitro. Heneberg P; Riegerová K; Kučera P PLoS One; 2015; 10(11):e0142953. PubMed ID: 26562153 [TBL] [Abstract][Full Text] [Related]
17. Pollen derived low molecular compounds enhance the human allergen specific immune response in vivo. Gilles-Stein S; Beck I; Chaker A; Bas M; McIntyre M; Cifuentes L; Petersen A; Gutermuth J; Schmidt-Weber C; Behrendt H; Traidl-Hoffmann C Clin Exp Allergy; 2016 Oct; 46(10):1355-65. PubMed ID: 27061126 [TBL] [Abstract][Full Text] [Related]
18. Effect of natural seasonal pollen exposure and repeated nasal allergen provocations on elevation of exhaled nitric oxide. Bergmann-Hug K; Wirth R; Henseler M; Helbling A; Pichler WJ; Schnyder B Allergy; 2009 Nov; 64(11):1629-34. PubMed ID: 19627276 [TBL] [Abstract][Full Text] [Related]
19. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Grindebacke H; Wing K; Andersson AC; Suri-Payer E; Rak S; Rudin A Clin Exp Allergy; 2004 Sep; 34(9):1364-72. PubMed ID: 15347368 [TBL] [Abstract][Full Text] [Related]
20. Increased number of CD34+ cells in nasal mucosa of allergic rhinitis patients: inhibition by a local corticosteroid. Sergejeva S; Malmhäll C; Lötvall J; Pullerits T Clin Exp Allergy; 2005 Jan; 35(1):34-8. PubMed ID: 15649263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]